Transfusion and Apheresis Science
Volume 42, Issue 3 , Pages 239-245 , June 2010

Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation

Received 16 May 2009

References 

  1. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. J Clin Oncol. 2002;20:405–412
  2. Miekarek M, Storer BE, Flowers MED, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1160–1168
  3. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40:1027–1032
  4. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007;25:4938–4945
  5. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood and marrow transplantation. Cancer Control. 2002;9:123–137
  6. Porter D, Levine JE. Graft versus host disease and graft versus leukemia after donor leukocyte infusion. Semin Hematol. 2005;43:53–61
  7. Loren AW, Porter DL. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol. 2006;18:107–114
  8. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase I trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107:1325–1331
  9. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  10. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JLM, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;18:975–980
  11. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  12. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leukemia Lymphoma. 1998;29:301–313
  13. Porter DL, Connors JM, Van Deerlin VMD, Duffy KM, McGarigle C, Saidman SL, et al. Graft versus tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17:1234–1243
  14. Peggs KS, Mackinnon S. Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol. 2001;8:349–354
  15. Roush KS, Hillyer CD. Donor lymphocyte infusion therapy. Transfus Med Rev. 2002;16:161–176
  16. Kobayashi K, Kami M, Murashige N, Kusumi E, Kishi Y, Hamaki T, et al. Outcomes of patients with acute leukemia who relapsed after reduced intensity stem cell transplantation from HLA identical or one antigen-mismatched related donors. Br J Haematol. 2005;129:795–802
  17. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41:483–493
  18. Fozza C, Szydlo RM, Abdel-Rehim MM, Nadal E, Goldman JM, Apperley JF, et al. Factors for graft versus host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol. 2007;136:833–836
  19. Sprangers B, Van Wijmeersch B, Fevery S, Waer M, Billiau AD. Experimental and clinical approaches for optimization of the graft versus leukemia effect. Nat Clin Pract. 2007;4:404–414
  20. Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O, et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblasic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:805–812
  21. Rezvani AR, Storb RF. Separation of graft vs tumor effects from graft vs host disease in allogeneic hematopoietic cell transplantation. J Autoimmun. 2008;30:172–179
  22. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia positive acute lymphoblastic leukemia relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia Res. 2009;33:174–177
  23. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D, et al. Donor lymphocyte infusions: factors predicting response and graft versus host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 2003;31:687–693
  24. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JAL, et al. Treatment of relapse after allogeneic bone marrow trasnplantation with reduced intensity conditioning (FLAG±ida) and second allogeneic stem cell transplant. Br J Haematol. 2001;115:622–629
  25. Campregher PV, Gooley T, Scott BL, Moravec C, Sandmaier B, Martin PJ, et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40:965–971
  26. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft versus host disease than DLI alone. Blood. 2007;110:2761–2763
  27. Marijt WAE, Heemskerk MHM, Koosterboer FM, Goulmy E, Kester MGD, Van der Hoorn MAWG, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742–2747

PII: S1473-0502(10)00063-7

doi: 10.1016/j.transci.2010.03.011

Transfusion and Apheresis Science
Volume 42, Issue 3 , Pages 239-245 , June 2010

Article Tools

* Image Usage & Resolution